Clariness today announces its support of YPrime’s ongoing commitment to enhance the patient and site eCOA experience by delivering insights from more than 2,000 patients in four countries, assessing patient demographics and psychographics.
Assessing the digital behaviours and trial awareness of a diverse international population, Clariness received patient insights across five therapeutic areas, including oncology, immunology, rare diseases, central nervous system, and dermatology.
“The insights Clariness provided were critical to our focus on improving the patient and site experience. For instance, older patients across all indications had a much higher digital literacy level, and higher compliance adherence, than we expected. The volume of responses, and the diversification of patients who provided input, has allowed us to make product enhancement and decisions faster and with more confidence,” said Mark Maietta, President of YPrime.
Clariness was tasked with providing insights from 1,600 patients, gathering data on digital device usage behaviours, app and notification preferences, and previous trial experiences. Clariness delivered insights from over 2,000 patients in just two months, which could be segmented by patient age, medical condition, education level, ethnicity, spoken language and more.
Michael Stadler, CEO and co-founder of Clariness, commented: “We were happy to support YPrime with these powerful patient insights. The more we learn about patient experiences, preferences and behaviours, the more we can collectively, as an industry, connect more patients with new medical therapies and treatments, on a global scale, and that’s what we’re here to do.”